Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Trial Details

NCT ID

NCT05257993

Phase

PHASE1 / PHASE2

Sponsor

Onconic Therapeutics Inc.

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• JPI-547
• modified FOLFIRINOX
• Gemcitabine-nab-paclitaxel

Locations (sample)

• Gyeonggi-do, South Korea|37.58944,126.76917
• Seoul, South Korea|37.566,126.9784
• Seoul, South Korea|37.566,126.9784
• Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

• \[Phase 1b/2\]
• Histologically or cytologically confirmed inoperable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC)
• Those with at least one measurable lesion in accordance with RECIST 1.1
• Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.